doi: 10.1016/j.pediatrneurol.2023.10.012.
- PMID: 37995414
- DOI: 10.1016/j.pediatrneurol.2023.10.012
Free article
Abstract
Background: Drug-resistant epilepsy (DRE) affects the development and quality of life of children and young adults. We analyzed the effectiveness and safety of purified CBD in this population.
Methods: A retrospective analysis of medical records of 139 children and young adults (54.7% female, median age 12.0 years) with DRE treated with purified CBD from 2018 to 2022 at five medical centers in Israel.
Results: The most common diagnosis was Lennox-Gastaut syndrome (37.4%) followed by Dravet syndrome (16.5%) and tuberous sclerosis complex (16.5%). Median purified CBD dose was 12.5 mg/kg (range 2.5 to 20.0), and median treatment duration was 9.0 months (range 0.5 to 48.0). Most patients (92.2%) had a reduced seizure frequency following treatment initiation; 41.1% had >50% reduction. Fifty-three patients (38.1%) had positive effects: improved alertness (31.7%), improved speech (10.1%), and achievement of new developmental milestones (2.2%). A multivariate linear model assessing predictive factors for seizure reduction demonstrated that patients previously treated with CBD oils, especially those with >50% seizure reduction on prior treatment, were also more likely to have a reduced seizure frequency while they were treated with purified CBD (P = 0.01, P < 0.0001). Development, diagnosis, age, purified CBD dose (0 to 10 mg/kg/day vs 10 to 20 mg/kg/day), and concomitant treatment with clobazam, valproic acid, or everolimus did not affect seizure reduction by purified CBD. The most common adverse events were irritability (20.9%) and drowsiness (12.9%).
Conclusion: Purified CBD is well-tolerated and effective in reducing seizure frequency in children and young adults with DRE.
Keywords: Children, Drug-resistant epilepsy, Purified cannabidiol, Seizure reduction, Young adults
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Michal Tzadok reports a relationship with LivaNova Plc that includes consulting or advisory. Rotem Pollack reports a relationship with Neopharm Israel that includes employment. Statistical analysis and medical writing support were provided by Medistat Ltd and MIMS Pte. Ltd and were funded by Jazz Pharmaceuticals Inc.
